Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FYN | P06241 | 3/20 | 0.47 |
| ▸ | KDR | P35968 | 2/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | TGFBR1 | P36897 | 2/20 | 0.41 |
| ▸ | TGFBR2 | P37173 | 2/20 | 0.41 |
| ▸ | KLKB1 | P03952 | 1/20 | 0.41 |
| ▸ | KLK1 | P06870 | 1/20 | 0.41 |
| ▸ | TLR9 | Q9NR96 | 1/20 | 0.40 |
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.40 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.40 |
| ▸ | HPGDS | O60760 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 2/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
| ▸ | POLB | P06746 | 2/20 | 0.39 |
| ▸ | MITF | O75030 | 1/20 | 0.39 |
| ▸ | RAD52 | P43351 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4161445 | 0.95 | KDR (0.48) | FYNKDRTGFBR1TGFBR2KLKB1 | |
| SCHEMBL3722416 | 0.92 | KDR (0.46) | FYNKDRTGFBR1TGFBR2KLKB1 | |
| SCHEMBL3730619 | 0.87 | TGFBR1 (0.47) | KDRTGFBR1TGFBR2KLKB1KLK1 | |
| SCHEMBL4161414 | 0.85 | TGFBR1 (0.47) | TGFBR1TGFBR2RAD52 | |
| SCHEMBL4151076 | 0.84 | HPGDS (0.59) | TGFBR1TGFBR2HPGDSMAPK8 | |
| SCHEMBL3723829 | 0.82 | TGFBR1 (0.48) | TGFBR1TGFBR2KLKB1KLK1 | |
| SCHEMBL3800944 | 0.81 | HPGDS (0.59) | TGFBR1TGFBR2HPGDS | |
| SCHEMBL3722355 | 0.78 | TGFBR1 (0.46) | TGFBR1TGFBR2HPGDS | |
| SCHEMBL3668426 | 0.78 | TGFBR1 (0.48) | TGFBR1TGFBR2 | |
| SCHEMBL3723221 | 0.77 | TGFBR1 (0.50) | TGFBR1TGFBR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8314112-B2 | Pyrrolopyrimidines and pyrrolopyridines | NOVARTIS AG (CH) | 2012-11-20 | — | — | US | claimed |
| US-20090181941-A1 | Pyrrolopyrimidines and Pyrrolopyridines | NOVARTIS AG (CH) | 2009-07-16 | — | — | US | claimed |
| US-8314112-B2 | Pyrrolopyrimidines and pyrrolopyridines | NOVARTIS AG (CH) | 2012-11-20 | — | — | US | disclosed |
| US-20090181941-A1 | Pyrrolopyrimidines and Pyrrolopyridines | NOVARTIS AG (CH) | 2009-07-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090181941-A1 | Pyrrolopyrimidines and Pyrrolopyridines | ALK, ACVR1, PTPN4 | FYN 349/4885KDR 124/4885HTT 1495/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.